Jérémy BEGUIN
New therapeutic strategy using a double deleted oncolytic Vaccinia virus encoding FCU1 protein
(TG6002) against canine cancers
Summary of the presentation :
Oncolytic virotherapy with tumor selective viruses, such as Vaccinia viruses (VV), offers a promising treatment modality for cancer. TG6002 is a recombinant oncolytic VV deleted in two viral genes (thymidine kinase and ribonucleotide reductase) and armed with the suicide gene FCU1 that encodes a bifunctional chimeric protein which efficiently catalyses the direct conversion of the nontoxic 5-fluorocytosine (5-FC) into the toxic metabolite 5-fluorouracil (5-FU). Canine tumors are relevant predictive preclinical surrogates for human oncology and can be used as preclinical models.
Here, we evaluate the replicative and infective capacities and the oncolytic potency of TG6002 using various models ( canine cell lines cultured in 2D and 3D, canine tumoral explants, xenograft models and dogs with spontaneous tumors).
TG6002 is able to infect and replicate in canine tumor cell lines and is oncolytic in both cell lines, xenograft model and canine mammary tumoral samples. Preliminary data on dogs diagnosed with cancer confirm the relevance of TG6002 in cancer treatment. This work also emphasizes the importance of a One Health approach in oncology.
Educational background :
2007-2012 : Diplôme de doctorat vétérinaire Ecole Nationale Vétérinaire d’Alfort – Maisons-Alfort
2016 : Master 2 biologie santé, cancérologie - Université Paris Sud - Orsay
2017 : Préparation d’une thèse de Sciences en Cancérologie – Université Paris Est – Créteil, portant sur l'évaluation d'un virus oncolytique dérivé du virus de la Vaccine sur des modèles de tumeurs spontanées chez le chien. Thèse en partenariat avec Transgene.
Professional background :
2013 - 2019 : Ecole Nationale Vétérinaire d'Alfort - Maisons Alfort : service de médecine interne consultant en cancérologie
2017-2019 : Transgene - Illkirch Graffenstaden : Collaborateur au sein de l’équipe vecteurs oncolytiques